Anergic cells generated by blocking CD28 and CD40 costimulatory pathways in vitro ameliorate collagen induced arthritis

Cellular Immunology

Volumn 254, Issue 1, 2008, Pages 39-45

  Li, Ling ^a   Wang, Houping ^b   Wang, Bin ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anergic cells; Antibody; Collagen induced arthritis (CIA); Costimulatory molecules; Cytokine

Indexed keywords

CD28 ANTIGEN; CD40 ANTIGEN; COLLAGEN TYPE 2; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; PHYTOHEMAGGLUTININ; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; CELL CONTACT; CELL CULTURE; CELL PROLIFERATION; CLONAL ANERGY; CONTROLLED STUDY; DISEASE COURSE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD28; ANTIGENS, CD40; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CLONAL ANERGY; CYTOKINES; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 55049131011     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.06.010     Document Type: Article

References (45)

1. Fox D.A. The role of T-cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum. 40 (1997) 598-609
2. MacDonald K.P., Nishioka Y., Lipsky P.E., and Thomas R. Functional CD40 ligand is expressed T cells in rheumatoid arthritis. J. Clin. Invest. 100 (1997) 2404-2414
3. Brand D.D., Latham K.A., and Rosloniec E.F. Collagen-induced arthritis. Nat. Protoc. 2 (2007) 1269-1275
4. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., and Ledbetter J.A. CTLA4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174 (1991) 561-569
5. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14 (1996) 233-258
6. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., Cho H.R., Aruff A., Hollenbaugh D., Linsley P.S., Winn K.J., and Pearson T.C. Long term acceptance of skin and cardiac allograft after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
7. Magott-Procelewska M. Costimulatory pathway as a basic mechanism of activating a tolerance signal in T cells. Ann. Transplant. 9 (2004) 13-18
8. Pollard K.M., Arnush M., Hultman P., and Kono D.H. Costimulation requirements of induced murine systemic autoimmune disease. J. Immunol. 173 (2004) 5880-5887
9. Durie F.H., Fava R.A., and Noelle R.J. Collagen induced arthritis as a model of rheumatoid arthritis. Clin. Immunol. Immunopathol. 73 (1994) 11-18
10. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., and Routsias J.G. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J. Autoimmun. 26 (2006) 165-171
11. Toubi E., and Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37 (2004) 457-464
12. Liu M.F., Chao S.C., Wang C.R., and Lei H.Y. Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 34 (2001) 107-113
13. Munroe M.E., and Bishop G.A. A costimulatory function for T cell CD40. J. Immunol. 178 (2007) 671-682
14. Verwilghen J., Lovis R., and De Boer M. Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J. Immunol. 153 (1994) 1378-1385
15. Ranheim E.A., and Kipps T.J. Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthtitis Rheum. 37 (1994) 1637-1646
16. Vincenti F. Costimulation blockade-what will the future bring?. Nephrol. Dial. Transplant. 22 (2007) 1293-1296
17. Vincenti F., and Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune disease and transplantation. Annu. Rev. Med. 58 (2007) 347-358
18. Schwartz R.H. Models of T cell anergy: is there a common molecular mechanism?. J. Exp. Med. 184 (1996) 1-8
19. Roy M., Aruffo A., Ledbetter J., Linsley P., Kehry M., and Noelle R. Studies on the interdependence of gp39 and B7 expression and function during antigen specific immune responses. Eur. J. Immunol. 25 (1995) 596-603
20. Griggs N.D., Agersborg S.S., Noelle R.J., Ledbetter J.A., Linsley P.S., and Tung K.S. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J. Exp. Med. 183 (1996) 801-810
21. Luo Z., Gotoh M., Grochowiecki T., Tanaka T., Kimura F., Kawashima H., Yagita H., Kumura K., and Miyasaka M. Anergic T cells generated in vitro suppress rejection response to islet allografts. Transplantation 69 (2000) 2144-2148
22. Yi-qun Z., Lorré K., de Boer M., and Ceuppens J.L. B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells. J. Immunol. 158 (1997) 4734-4740
23. Khoury S.J., Gallon L., Verburg R.R., Chandraker A., Peach R., Linsley P.S., Turka L.A., Hancock W.W., and Sayegh M.H. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J. Immunol. 157 (1996) 3700-3705
24. Hara Y., Kitazawa Y., Funeshima N., Kawasaki M., Sato Y., Tezuka K., Kimura H., Hatakeyama K., and Li XK. Anergic lymphocytes generated by blocking CD28 and ICOS pathways in vitro prolong rat cardiac graft survival. Int. Immunopharmacol. 6 (2006) 1143-1151
25. Lombardi G., Sidhu S., Batchelor R., and Lechler R. Anergic T cells as suppressor cells in vitro. Science 264 (1994) 1587-1589
26. Chai J.G., Bartok I., Chandler P., Vendetti S., and Antoniou A. Anergic T cells act as suppressor cells in vitro and in vivo. Eur. J. Immunol. 29 (1999) 686-692
27. Mannie M.D., Rendall S.K., Arnold P.Y., Nardella J.P., and White G.A. Anergy-associated T cell antigen presentation: a mechanism of infectious tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 157 (1996) 1062-1070
28. Walmsley M., Katsikis P.D., Abney E., Parry S., Williams R.O., Maini R.N., and Feldmann M. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 39 (1996) 495-503
29. Wang H., Ma B., Han Z., and Guo X. The mechanism of induction of anergic cells by CTLA4Ig. J. Shanghai Immunol. 20 (2000) 155-158
30. Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., Shimizu J., and Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10 (1998) 1969-1980
31. Vendetti S., Chai J.G., Dyson J., Simpson E., Lombardi G., and Lechler R. Anergic T cells inhibit the antigen-presenting function of dendritic cells. J. Immunol. 165 (2000) 1175-1181
32. Frasca L., Scotta C., Lombardi G., and Piccolella E. Human anergic CD4+T cells can act as suppressor cells by affecting autologous dendritic cell conditioning and survival. J. Immunol. 168 (2002) 1060-1068
33. Schwartz R.H. Natural regulatory T cells and self tolerance. Nat. Immunol. 6 (2005) 327-330
34. Taams L.S., van Rensen A.J., Poelen M.C., van Els C.A., Besseling A.C., Wagenaar J.P., van Eden W., and Wauben M.H. Anergic T cells actively suppress T cell responses via the antigen-presenting cell. Eur. J. Immunol. 28 (1998) 2902-2912
35. Akdis C.A., and Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 13 (1999) 603-609
36. Taams L.S., Boot E.P.J., van Eden W., and Wauben M.H.M. Anergic T cells modulate the T cell activating capacity of antigen presenting cells. J. Autoimmun. 14 (2000) 335-341
37. Doncarli A., Stasiuk L.M., Founier S., and Abehsira-Amar O. Conversion in vivo from an early dominant Th0/TH1 response to a Th2 phenotype during the development of collagen induced arthritis. Eur. J. Immunol. 27 (1997) 1451-1458
38. Carrier Y., Yuan J., Kuchroo V.K., and Weiner H.L. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J. Immunol. 178 (2007) 179-185
39. Morgan M.E., Flierman R., van Duivenvoorde L.M., Witteveen H.J., van Ewijk W., van Laar J.M., de Vries R.R., and Toes R.E. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 52 (2005) 2212-2221
40. Zheng Y., and Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8 (2007) 457-462
41. Marcelletti J.F., Ohara J., and Katz D.H. Collagen-induced arthritis in mice. Relationship of collagen-specific and total IgE synthesis to disease. J. Immunol. 147 (1991) 4185-4191
42. Phinn S.D., Morgan K., and Holt P.J. Collagen-induced arthritis: antibody production by lymphocytes in vitro. Clin. Exp. Rheumatol. 5 (1987) 127-134
43. Mukherjee P., Wu B., Mayton L., Kim S.H., Robbins P.D., and Wooley P.H. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann. Rheum. Dis. 62 (2003) 707-714
44. Cho Y.G., Cho M.L., Min S.Y., and Kim H.Y. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun. Rev. 7 (2007) 65-70
45. Webb L.M., Walmsley M.J., and Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for bothB7-1 and B7-2. Eur. J. Immunol. 26 (1996) 2320-2328